274 related articles for article (PubMed ID: 23451917)
1. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
Ghadaki B; Nazi I; Kelton JG; Arnold DM
Transfusion; 2013 Nov; 53(11):2807-12. PubMed ID: 23451917
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
[TBL] [Abstract][Full Text] [Related]
3. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
Cooper N; Scully M; Percy C; Nicolson PLR; Lowe G; Bagot CN; Thachil J; Grech H; Nokes T; Hill QA; Bradbury C; Talks K; Dutt T; Evans G; Pavord S; Wexler S; Charania A; Collington SJ; Ervin A; Ramscar N; Provan D
Br J Haematol; 2024 Jun; 204(6):2442-2452. PubMed ID: 38429869
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin receptor agonists: ten years later.
Ghanima W; Cooper N; Rodeghiero F; Godeau B; Bussel JB
Haematologica; 2019 Jun; 104(6):1112-1123. PubMed ID: 31073079
[TBL] [Abstract][Full Text] [Related]
5. Fostamatinib or Thrombopoietin for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost.
Dranitsaris G; Peevyhouse A; Wood T; Kreychman Y; Neuhalfen H; Moezi M
Acta Haematol; 2024; 147(3):333-343. PubMed ID: 37778326
[TBL] [Abstract][Full Text] [Related]
6. The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim.
Al-Samkari H; Schifferli A; Gonzalez-Lopez TJ
Br J Haematol; 2024 Apr; 204(4):1143-1145. PubMed ID: 38319005
[TBL] [Abstract][Full Text] [Related]
7. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
Janssens A; Rodeghiero F; Anderson D; Chong BH; Boda Z; Pabinger I; Červinek L; Terrell DR; Wang X; Franklin J
Ann Hematol; 2016 Jun; 95(7):1077-87. PubMed ID: 27130310
[TBL] [Abstract][Full Text] [Related]
8. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.
Grainger JD; Kühne T; Hippenmeyer J; Cooper N
Ann Hematol; 2021 Sep; 100(9):2143-2154. PubMed ID: 34308495
[TBL] [Abstract][Full Text] [Related]
9. Face validity of the Kids' ITP Tools (KIT) in the era of thrombopoietin receptor agonists.
McGuire C; Young NL; Livingston J; Dhir V; Blanchette VS; Kirby-Allen M; Klaassen RJ
Pediatr Blood Cancer; 2024 Apr; 71(4):e30888. PubMed ID: 38265264
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and outcomes among adults with immune thrombocytopenia receiving pharmaceutical second-line therapies: a retrospective cohort study using administrative claims data.
Liang Y; Rascati K; Barner JC; Lawson KA; Nair R
Curr Med Res Opin; 2024 May; 40(5):781-788. PubMed ID: 38465414
[TBL] [Abstract][Full Text] [Related]
11. Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study).
Jansen AJG; McDonald V; Newland A; Morgan M; Bastiaanse M; Wilson K; Eriksson D; Geldman E; Daykin-Pont O; Prince S; Zwaginga JJ
Hematology; 2023 Dec; 28(1):2267942. PubMed ID: 37818773
[TBL] [Abstract][Full Text] [Related]
12. European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
Barlassina A; González-López TJ; Cooper N; Zaja F
Platelets; 2023 Dec; 34(1):2170999. PubMed ID: 36803535
[TBL] [Abstract][Full Text] [Related]
13. Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists.
Rottenstreich A; Bussel JB
Br J Haematol; 2023 Dec; 203(5):872-885. PubMed ID: 37830251
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin.
Li Y; Kong F; Bai G; Jiang Y; Zhang W; Sun X; Sui X; Li Y; Ding M; Yuan D; Wang X; Fang X
Front Immunol; 2024; 15():1340908. PubMed ID: 38650933
[TBL] [Abstract][Full Text] [Related]
15. Long-term eltrombopag in children with chronic immune thrombocytopenia: A single-centre extended real-life observational study in China.
Wang Z; Wang N; Juntao O; Ma J; Dong S; Meng J; Liu J; Chen Z; Cheng X; Wu R
Br J Haematol; 2024 Mar; 204(3):1017-1023. PubMed ID: 38087811
[TBL] [Abstract][Full Text] [Related]
16. Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study.
Guillet S; Crickx E; Azzaoui I; Chappert P; Boutin E; Viallard JF; Rivière E; Gobert D; Galicier L; Malphettes M; Cheze S; Lefrere F; Audia S; Bonnotte B; Lambotte O; Noel N; Fain O; Moulis G; Hamidou M; Gerfaud-Valentin M; Marolleau JP; Terriou L; Martis N; Morin AS; Perlat A; Le Gallou T; Roy-Peaud F; Robbins A; Lega JC; Puyade M; Comont T; Limal N; Languille L; Zarrour A; Luka M; Menager M; Belmondo T; Hue S; Canoui-Poitrine F; Michel M; Godeau B; Mahévas M
Blood; 2023 Jun; 141(23):2867-2877. PubMed ID: 36893453
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China.
Wang Z; Zhang A; Xu Z; Wang N; Zhang J; Meng J; Dong S; Ma J; Hu Y; Ouyang J; Chen Z; An Q; Cheng X; Wu R
Br J Haematol; 2024 May; 204(5):1958-1965. PubMed ID: 38362793
[TBL] [Abstract][Full Text] [Related]
18. Romiplostim as an early treatment for refractory immune thrombocytopenia in a 2-month-old infant.
Chiba Y; Tasaka K; Matsubara K; Mori M; Muraoka M; Hamabata T; Nodomi S; Waki K
Pediatr Blood Cancer; 2024 Jun; 71(6):e30953. PubMed ID: 38520052
[No Abstract] [Full Text] [Related]
19. Real-world evidence confirms thrombopoietin receptor agonists are safe and effective for all stages of immune thrombocytopenia.
Provan D
Am J Hematol; 2024 Jan; 99(1):4-5. PubMed ID: 38063326
[No Abstract] [Full Text] [Related]
20. Antithrombotic and hemostatic stewardship: Evaluation of romiplostim for treatment of thrombocytopenia at a large academic medical center.
Wong A; Ahuja T; Cirrone F; Xiang E
J Oncol Pharm Pract; 2024 Mar; 30(2):246-250. PubMed ID: 37132025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
